Tag: Entera Bio Ltd (NASDAQ: ENTX)

Business

Entera Bio Ltd (NASDAQ: ENTX) Announces Outstanding Topline Phase 2 BMD Statistics for EB613

Entera Bio Ltd (NASDAQ: ENTX) has announced the concluding 6-month bone mineral density (BMD) consequences from the finished Phase 2 clinical trial of EB613 to cure osteoporosis. EB613 is an oral preparation of human parathyroid hormone (1-34), or PTH, sited to be the first oral bone-building product to treat osteoporosis […]